Rivoceranib
Rivoceranib Phase 2
Elevar Therapeutics · Phase 2 · Terminated · Enrollment 80
| Arm | Reported safety |
|---|---|
| Rivoceranib 700 mg | grade 3 or higher treatment-related adverse events: 70%, primary analysisdiscontinued for toxicity: 20%, primary analysis |
A count stays a count. This page does not turn a count into a percent.